The effect of transforming growth factor-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma.
This in vitro study was aimed at restitution of transforming growth factor (TGF)-beta 2-mediated suppression of T-lymphocyte activation within malignant gliomas. In early-passage tumor cell cultures of two glioblastomas (HTZ-153 and HTZ-209) and one malignant astrocytoma classified as World Health Organization Grade III (HTZ-243), autologous peripheral blood mononuclear cells were activated by interleukin-1 alpha and interleukin-2 in vitro (lymphokine-activated killer cells) and tested for cytotoxic and proliferative activity. In expression studies (Western blot and Northern hybridization) of all three tumors, TGF-beta could be detected at the protein and messenger ribonucleic acid (mRNA) levels. A polyclonal anti-TGF-beta neutralizing antibody did not enhance lymphocyte proliferation upon stimulation with tumor targets (3H-thymidine incorporation) and slightly stimulated lymphocyte cytotoxicity against autologous target cells. Preincubation of target cells for 12 hours with TGF-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides (S-ODN's) did, however, enhance lymphocyte proliferation up to 2.5-fold and autologous tumor cytotoxicity up to 60%, compared to controls not treated with S-ODN's. Incubation of tumor cells with TGF-beta 2-specific S-ODN's resulted in decreased TGF-beta-specific immunoreactivity in cultured glioma cells, in reduced TGF-beta 2 protein concentration (Western blot), and in a change in the expression pattern of TGF-beta 2 mRNA's. These observations may have implications for in vivo and in vitro activation of a cellular immune response against autologous malignant glioma cells.
Jachimczak
P
P
Department of Neurology, University of Würzburg, Germany.
Bogdahn
U
U
Schneider
J
J
Behl
C
C
Meixensberger
J
J
Apfel
R
R
Dörries
R
R
Schlingensiepen
K H
KH
Brysch
W
W
D015703:Antigens, CD / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D015152:Blotting, Northern; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000276:immunology*; D005910:Glioma / Q000276:immunology*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D016867:Immunocompromised Host / Q000187:drug effects*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000276:immunology; D016376:Oligonucleotides, Antisense / Q000494:pharmacology*; D010641:Phenotype; D012334:RNA, Neoplasm / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects; D016212:Transforming Growth Factor beta / Q000187:drug effects*; D014407:Tumor Cells, Cultured / Q000276:immunology
D015703:Antigens, CD; D000951:Antigens, Neoplasm; D016376:Oligonucleotides, Antisense; D012334:RNA, Neoplasm; D016212:Transforming Growth Factor beta